NCT03920852 is a Phase 1 clinical trial of Ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation.

Who is sponsoring NCT03920852?

NCT03920852 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03920852?

Interventions in NCT03920852: Ruxolitinib cream.

What condition does NCT03920852 study?

NCT03920852 studies Atopic Dermatitis.

Is NCT03920852 still recruiting?

NCT03920852 is currently completed. Last updated 17 February 2020.

Last reviewed 2020-02-17 · How we verify

NCT03920852

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Completed Phase 1 Last updated 17 February 2020

What this trial tests

Phase 1 trial testing Ruxolitinib cream in Atopic Dermatitis in 41 participants. Completed in 26 December 2019.

Timeline

30 May 2019

Primary endpoint
26 December 2019

26 December 2019

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	30 May 2019
Primary completion	26 December 2019
Estimated completion	26 December 2019
Sites	10 locations across Canada, United States

Drugs / interventions tested

Ruxolitinib cream — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Incyte Corporation — full company profile →

Who can join

Adults 12 to 65, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label maximum use trial to evaluate ruxolitinib safety and blood levels after its topical application twice daily to affected areas (≥ 25% BSA) in adolescent and adult participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al · · 2024 · cited 95× · PMID 37923366 · DOI 10.1136/ard-2023-223850
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
Bissonnette R, Call RS, Raoof T, Zhu Z, et al · · 2022 · cited 33× · PMID 35368221 · DOI 10.1007/s40257-022-00690-3
Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives.
Pareek A, Kumari L, Pareek A, Chaudhary S, et al · · 2024 · cited 27× · PMID 38474389 · DOI 10.3390/cells13050425
Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD, Fay BL, Connell AJ, Peel MT, et al · · 2020 · cited 19× · PMID 33658996 · DOI 10.3389/fimmu.2020.620098
Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib.
Owji S, Caldas SA, Ungar B. · · 2022 · cited 10× · PMID 36316998 · DOI 10.2147/jaa.s342051
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis.
Stein Gold L, Bissonnette R, Forman S, Zaenglein A, et al · · 2025 · cited 7× · PMID 39760983 · DOI 10.1007/s40257-024-00909-5
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I, Pikiewicz W, Kaminiów K. · · 2023 · cited 6× · PMID 38138551 · DOI 10.3390/molecules28248064

Verify or expand the search:

Other trials of Ruxolitinib cream

Trials testing the same drug.

NCT05906628 — Topical Ruxolitinib Evaluation in Chronic Hand Eczema · Phase 2 · completed
NCT05233410 — Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 · Phase 3 · withdrawn
NCT05219864 — Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 · Phase 3 · withdrawn
NCT05635838 — Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa · Phase 2 · completed
NCT05593432 — A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus · Phase 2 · completed

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03920852 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 17 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03920852.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing